MaaT Pharma SA

€1.09As of Sun 8 Nov 2026, 12:00 UTC
EPA:MAATHealthcare
Country France
PE (Fwd) •••
TSR 5Y CAGR (39.27%)
Div yield —
ROE —
Biotechnology
Beta (5Y) 0.62
PE TTM —
TSR TTM (74.65%)
Mkt cap €20.54M
ROIC (140.41%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
€1.23
13.21%
16.25%
Sell 4|10|1|0|6
4Q25
1Q26
2Q26
3Q26
Earnings per share€
0.01
0.01
0.02
0.02
18.16%
18.92%
27.75%
36.60%
Revenue€M
1.657
1.700
1.681
1.662
3.65%
5.65%
3.61%
0.74%
Peers (US$23.06M)
Cap (US$)
PE
28.20M
4.176x
Capital
TTM
5Y
10Y
Leveragex
1.724
(0.048)
—
EBIT/Intx
0.759
1.438
1.373
Own earn%
(114.29)
(274.64)
(284.77)
Sh yield%
39.92
23.77
20.50
Owners
Insiders/Inst%
10.26
38.37
Short interest%
0.53
SBC / revenue%
2.07
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
18
Op margin range%
31–40
$1 testx
−0.3
Incr. ROIC%
3